רווח תפעולי לפני ניכוי פחת: inflarx.de (IFRX)

Stable demand for inflammation treatment makes the InflaRx N.V. (IFRX) business non-cyclical, as confirmed by the EBITDA chart. The current 0.00 indicator determines the metric's magnitude, capturing the issuer's fundamental health. This trend is driven by the expansion of niche drugs in US hospitals, although European supply chains remain sensitive to geopolitical risks and export restrictions.
InflaRx (IFRX) - פילוחי מדדים ודוחות פיננסיים

This indicator measures net cash flow from operating activities before taxes and interest, allowing for an assessment of the business's actual ability to generate liquidity. For InflaRx N.V. (IFRX), this is a critical marker of the efficiency of biopharmaceutical production outsourcing, as the company's absolute operating profit in cash reflects the balance between external vendor costs and market revenue.